circulating tumor cells
Conditions
Interventions
Simultaneous colorectal cancer liver metastasis:Haemospasia
Simultaneous and heterochronous colorectal cancer liver metastasis:Tissue biopsy
Sponsors
The 10th People's Hospital affiliated to Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-70 years old (including the cut-off value), male or female; 2) Expected survival =3 months; 3) KPS score = 60 points, and there are no contraindications for various biochemical indicators; 4) ECOS PS 0 points; 5) Liver function Child-Pugh class A; 6) The primary disease is confirmed by pathology to be colorectal cancer, and the liver lesion is confirmed to be liver metastatic tumor by imaging examination or biopsy pathology; 7) Dynamic contrast-enhanced MRI of the liver was performed before surgery, and CRLM was assessed as unresectable at initial diagnosis (according to the eighth edition of TNM staging, the T stage of the tumor is T1-T3; there is no distant organ metastasis); 8) Imaging shows that the metastasis is limited to the liver, and there is no tumor thrombus or extrahepatic metastasis in blood vessels, bile ducts and other parts; a single tumor, the diameter of the tumor is > 5 cm; or multiple tumors, the number of tumors is > 5, and the maximum diameter is > 4 cm; 9) Pregnant women who are not pregnant or breastfeeding should take contraceptive measures within 6 months after the end of treatment; 10) Laboratory tests within 1 week before treatment (including conversion therapy and surgery) must meet the following standards: A) Routine blood tests: a) Hemoglobin (Hb) =90 g/L; b) Neutrophil count (ANC) =1.5×109/L; c) Platelet count (PLT) =75×109/L; B) Biochemical examination: a) Albumin (ALB) =35 g/L; b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 × ULN; c) Total bilirubin (TBIL) =1.5×ULN; d) Creatinine (Cr) = 1.5 × ULN or creatinine clearance (Ccr) = 60 mL/min; C) Electrolytes are basically normal or normal after treatment; D) Urinary protein <2+ or 24-hour urine protein quantitative test =1.0 g/L (for patients with urine protein =2+, a 24-hour urine protein quantitative test must be =1.0 g/L before they can be selected); E) Coagulation function: a) International standard ratio (INR) or prothrombin time (PT) = 1.2 × ULN; b) Activated partial coagulation time (APTT) =1.5×ULN; F) T3 and T4 levels =2×ULN?
Exclusion criteria
Exclusion criteria: 1) Pathologically diagnosed as hepatocellular carcinoma, mixed hepatocellular-intrahepatic cholangiocarcinoma or other non-cholangiocytic malignant tumors; 2) Expected survival period 10 mg) or other types of immunosuppressive therapy, topical or oral corticosteroids can be included 10) Acute infectious diseases requiring treatment; 11) HIV positive; 12) Previous history of psychotropic drugs, alcohol or drug abuse; 13) Have obvious bleeding symptoms or clear bleeding tendency in the past 3 months; 14) Those who are allergic or suspected of being allergic to the trial drug; 15) Hypertensive patients have poor blood pressure control after antihypertensive drug treatment (systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg); 16) Metastasis to other sites other than liver metastasis or combined with tumors other than colon cancer; 17) Those who have uncontrollable hepatic encephalopathy, ascites, Gilbert syndrome, sclerosing cholangitis, etc.; who are combined with other organ dysfunction and are not expected to tolerate surgery or liver resection; 18) Anyone else who the researcher thinks cannot be included in the group
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| object response rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall Survival, OS;Adverse events of chemotherapy; | — |
Countries
China
Contacts
Public ContactLi Jun
The 10th People's Hospital affiliated to Tongji University
Outcome results
None listed